in collaboration with:

ERASMUS UNIVERSITEIT ROTTERDAM
INSTITUTE OF HEALTH POLICY & MANAGEMENT

Maastricht University

Lenalidomide with rituximab for previously treated follicular lymphoma and marginal zone lymphoma:

ERRATUM to
Addendum to the ERG report in response to company addendum for the amended follicular lymphoma only population

This document contains errata with respect to the addendum to the ERG report. The ERG noted that in the company model, the default for the time to next anti-lymphoma treatment (TTNLT) curve was set to generalized gamma, while in the company addendum the curve that was actually used was log-normal. This only affected the analyses for the R-mono comparison as in the other comparisons, the ERG actively changed the TTNLT curve. The ERG has therefore re-ran the R-mono analyses and provides here the corrected results in tables as well as in the text of the report.

The table below lists the page to be replaced in the original document and the nature of the change:

Page nr:	**Change:**
49-51	Text and Tables 5.10 and 5.11 deterministic and probabilistic results R-mono
57-60	Figures 5.17 to 5.23 CEACs for R-mono comparison
61	Conclusions: ICERs for R-mono comparison
70-73	Tables 6.13 to 6.18 ERG base-case results for R-mono comparison
83-87	Tables 6.31 to 6.36 ERG scenarios for R-mono comparison

which resulted in an ICER that ranged from £17,312 to £30,404. Finally, for the R-mono deterministic comparison, incremental costs varied from [redacted] to [redacted] and incremental QALYs from [redacted] to [redacted] with resulting ICERs ranging from £14,504 to £25,535.

The probabilistic ERG base-case (based on 1,000 iterations) for R^2 versus R-CHOP ranged from £16,874 to £44,888. For R^2 versus R-CVP, the ICER ranged from £23,135 to £59,810 and for R^2 versus R-mono, it ranged from £18,816 to £26,728. Compared with the deterministic base-case results, the ERG PSA resulted in higher ICERs, similar to what was seen in the company analyses. Particularly for the Weibull and Gompertz OS curves in the R-CHOP and R-CVP comparisons, the probabilistic ICER would sometimes be around twice the value of the deterministic ICER. For all the other OS curves, the differences between deterministic and probabilistic ICERs were more modest, although still considerable at times (see Table 5.11). The CEACs of all analyses are presented in Figures 5.6 to 5.23.

Table 5.1: ERG pairwise deterministic base-case results

Technologies	OS curve	Total costs	Total QALYs	Incremental costs	Incremental QALYs	ICER (£/QALY)
Deterministic ERG base-case for R^2 versus R-CHOP						
R^2	Weibull	[redacted]	[redacted]	[redacted]	[redacted]	£21,781
R-CHOP	Weibull	[redacted]	[redacted]			
R^2	Exponential	[redacted]	[redacted]	[redacted]	[redacted]	£16,581
R-CHOP	Exponential	[redacted]	[redacted]			
R^2	Log-normal	[redacted]	[redacted]	[redacted]	[redacted]	£14,531
R-CHOP	Log-normal	[redacted]	[redacted]			
R^2	Log-logistic	[redacted]	[redacted]	[redacted]	[redacted]	£17,146
R-CHOP	Log-logistic	[redacted]	[redacted]			
R^2	Gen gamma	[redacted]	[redacted]	[redacted]	[redacted]	£12,941
R-CHOP	Gen gamma	[redacted]	[redacted]			
R^2	Gompertz	[redacted]	[redacted]	[redacted]	[redacted]	£20,019
R-CHOP	Gompertz	[redacted]	[redacted]			
Deterministic ERG base-case for R^2 versus R-CVP						
R^2	Weibull	[redacted]	[redacted]	[redacted]	[redacted]	£30,404
R-CVP	Weibull	[redacted]	[redacted]			
R^2	Exponential	[redacted]	[redacted]	[redacted]	[redacted]	£22,742
R-CVP	Exponential	[redacted]	[redacted]			
R^2	Log-normal	[redacted]	[redacted]	[redacted]	[redacted]	£19,658
R-CVP	Log-normal	[redacted]	[redacted]			
R^2	Log-logistic	[redacted]	[redacted]	[redacted]	[redacted]	£23,529
R-CVP	Log-logistic	[redacted]	[redacted]			
R^2	Gen gamma	[redacted]	[redacted]	[redacted]	[redacted]	£17,312
R-CVP	Gen gamma	[redacted]	[redacted]			
R^2	Gompertz	[redacted]	[redacted]	[redacted]	[redacted]	£27,767
R-CVP	Gompertz	[redacted]	[redacted]			
Deterministic ERG base-case for R^2 versus R-mono						
R^2	Weibull	[redacted]	[redacted]	[redacted]	[redacted]	£21,341
R-mono	Weibull	[redacted]	[redacted]			

R^2	Exponential	[redacted]	[redacted]	[redacted]	[redacted]	£17,931
R-mono	Exponential	[redacted]	[redacted]			
R^2	Log-normal	[redacted]	[redacted]	[redacted]	[redacted]	£16,951
R-mono	Log-normal	[redacted]	[redacted]			
R^2	Log-logistic	[redacted]	[redacted]	[redacted]	[redacted]	£17,432
R-mono	Log-logistic	[redacted]	[redacted]			
R^2	Gengamma	[redacted]	[redacted]	[redacted]	[redacted]	£14,504
R-mono	Gengamma	[redacted]	[redacted]			
R^2	Gompertz	[redacted]	[redacted]	[redacted]	[redacted]	£25,535
R-mono	Gompertz	[redacted]	[redacted]			
ERG = Evidence Review Group = ICER = incremental cost effectiveness ratio; QALY = quality-adjusted life year						

Table 5.2: ERG probabilistic base-case results

Technologies	OS curve	Total costs	Total QALYs	Incremental costs	Incremental QALYs	ICER (£/QALY)
Probabilistic ERG base-case for R^2 versus R-CHOP						
R^2	Weibull	[redacted]	[redacted]	[redacted]	[redacted]	£44,888
R-CHOP	Weibull	[redacted]	[redacted]			
R^2	Exponential	[redacted]	[redacted]	[redacted]	[redacted]	£17,138
R-CHOP	Exponential	[redacted]	[redacted]			
R^2	Log-normal	[redacted]	[redacted]	[redacted]	[redacted]	£17,177
R-CHOP	Log-normal	[redacted]	[redacted]			
R^2	Log-logistic	[redacted]	[redacted]	[redacted]	[redacted]	£20,800
R-CHOP	Log-logistic	[redacted]	[redacted]			
R^2	Gen gamma	[redacted]	[redacted]	[redacted]	[redacted]	£16,874
R-CHOP	Gen gamma	[redacted]	[redacted]			
R^2	Gompertz	[redacted]	[redacted]	[redacted]	[redacted]	£30,229
R-CHOP	Gompertz	[redacted]	[redacted]			
Probabilistic ERG base-case for R^2 versus R-CVP						
R^2	Weibull	[redacted]	[redacted]	[redacted]	[redacted]	£59,810
R-CVP	Weibull	[redacted]	[redacted]			
R^2	Exponential	[redacted]	[redacted]	[redacted]	[redacted]	£23,583
R-CVP	Exponential	[redacted]	[redacted]			
R^2	Log-normal	[redacted]	[redacted]	[redacted]	[redacted]	£23,135
R-CVP	Log-normal	[redacted]	[redacted]			
R^2	Log-logistic	[redacted]	[redacted]	[redacted]	[redacted]	£32,899
R-CVP	Log-logistic	[redacted]	[redacted]			
R^2	Gen gamma	[redacted]	[redacted]	[redacted]	[redacted]	£24,778
R-CVP	Gen gamma	[redacted]	[redacted]			
R^2	Gompertz	[redacted]	[redacted]	[redacted]	[redacted]	£43,915
R-CVP	Gompertz	[redacted]	[redacted]			
Probabilistic ERG base-case for R^2 versus R-mono						
R^2	Weibull	[redacted]	[redacted]	[redacted]	[redacted]	£24,958

R-mono	Weibull	[redacted]	[redacted]			
R^2	Exponential	[redacted]	[redacted]	[redacted]	[redacted]	£18,816
R-mono	Exponential	[redacted]	[redacted]			
R^2	Log-normal	[redacted]	[redacted]	[redacted]	[redacted]	£19,169
R-mono	Log-normal	[redacted]	[redacted]			
R^2	Log-logistic	[redacted]	[redacted]	[redacted]	[redacted]	£19,775
R-mono	Log-logistic	[redacted]	[redacted]			
R^2	Gen gamma	[redacted]	[redacted]	[redacted]	[redacted]	£25,394
R-mono	Gen gamma	[redacted]	[redacted]			
R^2	Gompertz	[redacted]	[redacted]	[redacted]	[redacted]	£26,728
R-mono	Gompertz	[redacted]	[redacted]			
ERG = Evidence Review Group = ICER = incremental cost effectiveness ratio; QALY = quality-adjusted life year						

Figure 5.1: ERG base-case cost effectiveness acceptability curve for R^2 versus R-CHOP: Weibull OS



Figure 5.2: ERG base-case cost effectiveness acceptability curve for R^2 versus R-CVP: Gompertz OS



Figure 5.3: ERG base-case cost effectiveness acceptability curve for R^2 versus R-mono: Weibull OS



Figure 5.4: ERG base-case cost effectiveness acceptability curve for R^2 versus R-mono: exponential OS



Figure 5.5: ERG base-case cost effectiveness acceptability curve for R^2 versus R-mono: log-normal OS



Figure 5.6: ERG base-case cost effectiveness acceptability curve for R^2 versus R-mono: log-logistic OS



Figure 5.7: ERG base-case cost effectiveness acceptability curve for R^2 versus R-mono: generalized gamma OS



Figure 5.8: ERG base-case cost effectiveness acceptability curve for R^2 versus R-mono: Gompertz OS



5.3.2 Additional exploratory analyses performed based on the ERG base-case

Additional sensitivity analyses were performed to examine the potential impact of alternative assumptions on the cost effectiveness estimates. These were all performed using the ERG base-case. Results are presented in Tables 6.19 to 6.36 in Section 6 of this report.

Exploratory analyses using the ERG base-case:

1. Alternative PFS distributions: use Weibull for PFS both arms (for the R-mono comparison, generalised gamma was used as the alternative PFS distribution) (section 5.2.6)
2. Alternative PFS distributions: use exponential For PFS R^2 and Weibull for PFS comparator (not applied to R-mono comparison) (section 5.2.6)
3. Treatment waning effect after three-year cut-off (section 5.2.6)
4. Treatment waning effect after seven-year cut-off (section 5.2.6)
5. Adverse events for comparator taken from Van Oers et al. (2006)[11] (Not applicable in R-mono comparison) (section 5.2.7)
6. Apply same subsequent treatment costs for R^2 as for R-CHOP/R-CVP (Not applicable in R-mono comparison) (section 5.2.9)
7. Alternative utilities taken from Wild et al. (2006)[22] 0.805 for PF, 0.736 for PP off treatment, and 0.62 for PP on treatment (section 5.2.8)
8. Source for R-CHOP efficacy taken from Van Oers et al. (Not applicable in R-mono comparison) (section 5.2.6)
9. Alternative utilities taken for PP states taken from Pereira et al. (2010)[23] 0.45 for both PP states. (section 5.2.8)

5.3.3 Subgroup analyses performed based on the ERG base-case

No subgroup analyses were performed.

5.4 Conclusions of the cost effectiveness section

The main concern of the ERG in the original ERG report[1] was the questionable trustworthiness of R^2 efficacy resulting from the indirect comparison, which seemed to be inflated relative to the direct comparison data from AUGMENT. Although the ERG did not have the necessary data to quantify this uncertainty, it may have lowered the ICER substantially. This issue still applies to all the analyses presented here. The likely overestimation of utility values also still applies.

The ERG had concerns about the way survival curves were selected and validated. For the FL only analyses presented in the company addendum, overall survival as predicted by the parametric survival curves was very different from overall survival in the original submission. No clinical validation of these new OS curves was performed.

The ERG made various adjustments to the company base-case in the addendum.[2] The probabilistic ERG base-case for R^2 versus R-CHOP ranged from £16,874 to £44,888 per QALY gained (based on 1,000 iterations). For R^2 versus R-CVP, the ICER ranged from £23,135 to £59,810 and for R^2 versus R-mono, it ranged from £18,816 to £26,728.

Deterministic scenario analyses were performed to examine the potential impact of alternative assumptions on the cost-effectiveness estimates. For the R-CHOP/R-CVP comparisons, using R-CHOP and R-CVP efficacy from van Oers et al. would change the ICER substantially, but not always in the same direction. Alternative assumptions regarding lowered utilities in the PP health states and the time point at which treatment waning start could also change the ICER substantially, dependent on the OS curves chosen. In general, for the R-CHOP/R-CVP comparison it can be said that the model seems instable and results are highly dependent on the assumptions applied, with ICERs ranging between dominant and dominated. For the R-mono comparison, the ICERs are much less volatile, but still ranging between £11,539 and £42,448.

Of note, a full incremental analysis would result in R-CHOP being strictly dominated by definition (being equally effective and more costly than R-CVP), and the relevant ICER would therefore always be R^2 versus R-CVP. For R-mono, a full incremental analysis is not applicable, because costs and QALYs for R^2 are different in this comparison.

The main conclusion of the original ERG report[1] still applies, that is, even though the ERG base-case ICER for R-CHOP was below £20,000, the uncertainty around the cost effectiveness of R^2 is substantial, mainly caused by the possible bias introduced by the indirect treatment comparison, which could not be accounted for in the ERG analyses. In addition, specific to the FL only population analyses presented in the company addendum,[2] the uncertainty around the OS estimates and the lack of clinical validation of these estimates would warrant even more caution in the interpretation of results. The ICER for R-CVP is higher and suffers from the same uncertainty.

Table 6.3: Deterministic ERG base-case for R^2 versus R-CVP comparison: Gompertz OS

Technologies	Total costs	Total QALYs	Incremental costs	Incremental QALYs	ICER (£/QALY)
CS original base-case					
R^2	[redacted]	[redacted]	[redacted]	[redacted]	£23,746
R-CVP	[redacted]	[redacted]			
Fixing violations (2, use pooled R-CHOP/R-CVP subs Tx insyead of mixed R-chemo)					
R^2	[redacted]	[redacted]	[redacted]	[redacted]	£24,841
R-CVP	[redacted]	[redacted]			
Fixing violations (3, cap utilities at the general population level)					
R^2	[redacted]	[redacted]	[redacted]	[redacted]	£26,088
R-CVP	[redacted]	[redacted]			
Matter of judgement (4, use gompertz for OS in both arms)					
R^2	[redacted]	[redacted]	[redacted]	[redacted]	£21,863
R-CVP	[redacted]	[redacted]			
Matter of judgement (5, use log-logistic for PFS in R2 and Weibull for PFS comparator)					
R^2	[redacted]	[redacted]	[redacted]	[redacted]	£27,991
R-CVP	[redacted]	[redacted]			
Matter of judgement (6, use log-logistic for TTNLT both arms)					
R^2	[redacted]	[redacted]	[redacted]	[redacted]	£23,844
R-CVP	[redacted]	[redacted]			
ERG base-case (deterministic)					
R^2	[redacted]	[redacted]	[redacted]	[redacted]	£27,767
R-CVP	[redacted]	[redacted]			
ERG base-case (probabilistic)					
R^2	[redacted]	[redacted]	[redacted]	[redacted]	£43,915
R-CVP	[redacted]	[redacted]			

Table 6.4: Deterministic ERG base-case for R^2 versus R-mono comparison: Weibull OS

Technologies	Total costs	Total QALYs	Incremental costs	Incremental QALYs	ICER (£/QALY)
CS original base-case					
R^2	[redacted]	[redacted]	[redacted]	[redacted]	£20,274
R-mono	[redacted]	[redacted]			
Fixing violations (3, cap utilities at the general population level)					
R^2	[redacted]	[redacted]	[redacted]	[redacted]	£21,341
R-mono	[redacted]	[redacted]			
Matter of judgement (4, use weibull for OS both arms)					
R^2	[redacted]	[redacted]	[redacted]	[redacted]	£20,274
R-mono	[redacted]	[redacted]			
Base-case (deterministic)					

R^2	[redacted]	[redacted]	[redacted]	[redacted]	£21,341
R-mono	[redacted]	[redacted]			
Base-case (probabilistic)					
R^2	[redacted]	[redacted]	[redacted]	[redacted]	£24,958
R-mono	[redacted]	[redacted]			

Table 6.5: Deterministic ERG base-case for R^2 versus R-mono comparison: exponential OS

Technologies	Total costs	Total QALYs	Incremental costs	Incremental QALYs	ICER (£/QALY)
CS original base-case					
R^2	[redacted]	[redacted]	[redacted]	[redacted]	£20,274
R-mono	[redacted]	[redacted]			
Fixing violations (3, cap utilities at the general population level)					
R^2	[redacted]	[redacted]	[redacted]	[redacted]	£21,341
R-mono	[redacted]	[redacted]			
Matter of judgement (4, use exponential for OS both arms)					
R^2	[redacted]	[redacted]	[redacted]	[redacted]	£17,174
R-mono	[redacted]	[redacted]			
Base-case (deterministic)					
R^2	[redacted]	[redacted]	[redacted]	[redacted]	£17,931
R-mono	[redacted]	[redacted]			
Base-case (probabilistic)					
R^2	[redacted]	[redacted]	[redacted]	[redacted]	£18,816
R-mono	[redacted]	[redacted]			

Table 6.6: Deterministic ERG base-case for R^2 versus R-mono comparison: log-normal OS

Technologies	Total costs	Total QALYs	Incremental costs	Incremental QALYs	ICER (£/QALY)
CS original base-case					
R^2	[redacted]	[redacted]	[redacted]	[redacted]	£20,274
R-mono	[redacted]	[redacted]			
Fixing violations (3, cap utilities at the general population level)					
R^2	[redacted]	[redacted]	[redacted]	[redacted]	£21,341
R-mono	[redacted]	[redacted]			
Matter of judgement (4, use log-normal for OS both arms)					
R^2	[redacted]	[redacted]	[redacted]	[redacted]	£16,284
R-mono	[redacted]	[redacted]			
Base-case (deterministic)					
R^2	[redacted]	[redacted]	[redacted]	[redacted]	£16,951
R-mono	[redacted]	[redacted]			
Base-case (probabilistic)					
R^2	[redacted]	[redacted]	[redacted]	[redacted]	£19,169
R-mono	[redacted]	[redacted]			

Table 6.7: Deterministic ERG base-case for R^2 versus R-mono comparison: log-logistic OS

Technologies	Total costs	Total QALYs	Incremental costs	Incremental QALYs	ICER (£/QALY)
CS original base-case					
R^2	[redacted]	[redacted]	[redacted]	[redacted]	£20,274
R-mono	[redacted]	[redacted]			
Fixing violations (3, cap utilities at the general population level)					
R^2	[redacted]	[redacted]	[redacted]	[redacted]	£21,341
R-mono	[redacted]	[redacted]			
Matter of judgement (4, use log-logistic for OS both arms)					
R^2	[redacted]	[redacted]	[redacted]	[redacted]	£16,722
R-mono	[redacted]	[redacted]			
Base-case (deterministic)					
R^2	[redacted]	[redacted]	[redacted]	[redacted]	£17,432
R-mono	[redacted]	[redacted]			
Base-case (probabilistic)					
R^2	[redacted]	[redacted]	[redacted]	[redacted]	£19,775
R-mono	[redacted]	[redacted]			

Table 6.8: Deterministic ERG base-case for R^2 versus R-mono comparison: generalized gamma OS

Technologies	Total costs	Total QALYs	Incremental costs	Incremental QALYs	ICER (£/QALY)
CS original base-case					
R^2	[redacted]	[redacted]	[redacted]	[redacted]	£20,274
R-mono	[redacted]	[redacted]			
Fixing violations (3, cap utilities at the general population level)					
R^2	[redacted]	[redacted]	[redacted]	[redacted]	£21,341
R-mono	[redacted]	[redacted]			
Matter of judgement (4, use gengamma for OS both arms)					
R^2	[redacted]	[redacted]	[redacted]	[redacted]	£14,037
R-mono	[redacted]	[redacted]			
Base-case (deterministic)					
R^2	[redacted]	[redacted]	[redacted]	[redacted]	£14,504
R-mono	[redacted]	[redacted]			
Base-case (probabilistic)					
R^2	[redacted]	[redacted]	[redacted]	[redacted]	£25,394
R-mono	[redacted]	[redacted]			

Table 6.9: Deterministic ERG base-case for R^2 versus R-mono comparison: Gompertz OS

Technologies	Total costs	Total QALYs	Incremental costs	Incremental QALYs	ICER (£/QALY)
CS original base-case					
R^2	[redacted]	[redacted]	[redacted]	[redacted]	£20,274
R-mono	[redacted]	[redacted]			
Fixing violations (3, cap utilities at the general population level)					
R^2	[redacted]	[redacted]	[redacted]	[redacted]	£21,341
R-mono	[redacted]	[redacted]			
Matter of judgement (4, use gompertz for OS both arms)					
R^2	[redacted]	[redacted]	[redacted]	[redacted]	£24,126
R-mono	[redacted]	[redacted]			
Base-case (deterministic)					
R^2	[redacted]	[redacted]	[redacted]	[redacted]	£25,535
R-mono	[redacted]	[redacted]			
Base-case (probabilistic)					
R^2	[redacted]	[redacted]	[redacted]	[redacted]	£26,728
R-mono	[redacted]	[redacted]			

Table 6.10: Deterministic scenario analyses (conditional on ERG base-case) for R^2 versus R-CHOP: Weibull OS

Technologies	Total costs	Total QALYs	Incremental costs	Incremental QALYs	ICER (£/QALY)
ERG base-case					
R^2	[redacted]	[redacted]	[redacted]	[redacted]	£21,781
R-CHOP	[redacted]	[redacted]			
Use Weibull for PFS both arms					
R^2	[redacted]	[redacted]	[redacted]	[redacted]	£23,163
R-CHOP	[redacted]	[redacted]			
Use exponential For PFS R2 and Weibull for PFS comparator					
R^2	[redacted]	[redacted]	[redacted]	[redacted]	£19,630
R-CHOP	[redacted]	[redacted]			
Treatment waning effect at 3 years					
R^2	[redacted]	[redacted]	[redacted]	[redacted]	£16,107
R-CHOP	[redacted]	[redacted]			
Treatment waning effect at 7 years					
R^2	[redacted]	[redacted]	[redacted]	[redacted]	£39,668
R-CHOP	[redacted]	[redacted]			

Use Weibull for PFS both arms					
R^2	[redacted]	[redacted]	[redacted]	[redacted]	£29,034
R-CVP	[redacted]	[redacted]			
Use exponential For PFS R2 and Weibull for PFS comparator					
R^2	[redacted]	[redacted]	[redacted]	[redacted]	£25,791
R-CVP	[redacted]	[redacted]			
Treatment waning effect at 3 years					
R^2	[redacted]	[redacted]	[redacted]	[redacted]	£18,657
R-CVP	[redacted]	[redacted]			
Treatment waning effect at 7 years					
R^2	[redacted]	[redacted]	[redacted]	[redacted]	Dominated
R-CVP	[redacted]	[redacted]			
Adverse events for comparator taken from publication					
R^2	[redacted]	[redacted]	[redacted]	[redacted]	£30,072
R-CVP	[redacted]	[redacted]			
Apply same subsequent treatment costs					
R^2	[redacted]	[redacted]	[redacted]	[redacted]	£31,589
R-CVP	[redacted]	[redacted]			
Alternative utilities for PP states from Wild et al. (0.62)					
R^2	[redacted]	[redacted]	[redacted]	[redacted]	£40,523
R-CVP	[redacted]	[redacted]			
Source for R-CHOP/R-CVP efficacy from van Oers					
R^2	[redacted]	[redacted]	[redacted]	[redacted]	£2,064,117
R-CVP	[redacted]	[redacted]			
Alternative utilities for PP states from Pereira et al. (0.45)					
R^2	[redacted]	[redacted]	[redacted]	[redacted]	£70,564
R-CVP	[redacted]	[redacted]			

Table 6.11: Deterministic scenario analyses (conditional on ERG base-case) for R^2 versus R-mono: Weibull OS

Technologies	Total costs	Total QALYs	Incremental costs	Incremental QALYs	ICER (£/QALY)
ERG base-case					
R^2	[redacted]	[redacted]	[redacted]	[redacted]	£21,341
R-mono	[redacted]	[redacted]			
Use Generalised gamma for PFS both arms					
R^2	[redacted]	[redacted]	[redacted]	[redacted]	£20,895
R-mono	[redacted]	[redacted]			
Treatment waning effect at 3 years					
R^2	[redacted]	[redacted]	[redacted]	[redacted]	£36,561
R-mono	[redacted]	[redacted]			

Treatment waning effect at 7 years					
R^2	[redacted]	[redacted]	[redacted]	[redacted]	£16,066
R-mono	[redacted]	[redacted]			
Apply same subsequent treatment costs					
R^2	[redacted]	[redacted]	[redacted]	[redacted]	£24,098
R-mono	[redacted]	[redacted]			
Alternative utilities for PP states from Wild et al. (0.62)					
R^2	[redacted]	[redacted]	[redacted]	[redacted]	£18,477
R-mono	[redacted]	[redacted]			
Alternative utilities for PP states from Pereira et al. (0.45)					
R^2	[redacted]	[redacted]	[redacted]	[redacted]	£16,281
R-mono	[redacted]	[redacted]			

Table 6.12: Deterministic scenario analyses (conditional on ERG base-case) for R^2 versus R-mono: exponential OS

Technologies	Total costs	Total QALYs	Incremental costs	Incremental QALYs	ICER (£/QALY)
ERG base-case					
R^2	[redacted]	[redacted]	[redacted]	[redacted]	£17,931
R-mono	[redacted]	[redacted]			
Use Generalised gamma for PFS both arms					
R^2	[redacted]	[redacted]	[redacted]	[redacted]	£17,564
R-mono	[redacted]	[redacted]			
Treatment waning effect at 3 years					
R^2	[redacted]	[redacted]	[redacted]	[redacted]	£26,749
R-mono	[redacted]	[redacted]			
Treatment waning effect at 7 years					
R^2	[redacted]	[redacted]	[redacted]	[redacted]	£14,456
R-mono	[redacted]	[redacted]			
Apply same subsequent treatment costs					
R^2	[redacted]	[redacted]	[redacted]	[redacted]	£20,156
R-mono	[redacted]	[redacted]			
Alternative utilities for PP states from Wild et al. (0.62)					
R^2	[redacted]	[redacted]	[redacted]	[redacted]	£16,370
R-mono	[redacted]	[redacted]			
Alternative utilities for PP states from Pereira et al. (0.45)					
R^2	[redacted]	[redacted]	[redacted]	[redacted]	£15,061
R-mono	[redacted]	[redacted]			

Table 6.13: Deterministic scenario analyses (conditional on ERG base-case) for R^2 versus R-mono: log-normal OS

Technologies	Total costs	Total QALYs	Incremental costs	Incremental QALYs	ICER (£/QALY)
ERG base-case					
R^2	[redacted]	[redacted]	[redacted]	[redacted]	£16,951
R-mono	[redacted]	[redacted]			
Use Generalised gamma for PFS both arms					
R^2	[redacted]	[redacted]	[redacted]	[redacted]	£16,610
R-mono	[redacted]	[redacted]			
Treatment waning effect at 3 years					
R^2	[redacted]	[redacted]	[redacted]	[redacted]	£26,191
R-mono	[redacted]	[redacted]			
Treatment waning effect at 7 years					
R^2	[redacted]	[redacted]	[redacted]	[redacted]	£13,776
R-mono	[redacted]	[redacted]			
Apply same subsequent treatment costs					
R^2	[redacted]	[redacted]	[redacted]	[redacted]	£19,020
R-mono	[redacted]	[redacted]			
Alternative utilities for PP states from Wild et al. (0.62)					
R^2	[redacted]	[redacted]	[redacted]	[redacted]	£15,785
R-mono	[redacted]	[redacted]			
Alternative utilities for PP states from Pereira et al. (0.45)					
R^2	[redacted]	[redacted]	[redacted]	[redacted]	£14,776
R-mono	[redacted]	[redacted]			

Table 6.14: Deterministic scenario analyses (conditional on ERG base-case) for R^2 versus R-mono: log-logistic OS

Technologies	Total costs	Total QALYs	Incremental costs	Incremental QALYs	ICER (£/QALY)
ERG base-case					
R^2	[redacted]	[redacted]	[redacted]	[redacted]	£17,432
R-mono	[redacted]	[redacted]			
Use Generalised gamma for PFS both arms					
R^2	[redacted]	[redacted]	[redacted]	[redacted]	£17,078
R-mono	[redacted]	[redacted]			
Treatment waning effect at 3 years					
R^2	[redacted]	[redacted]	[redacted]	[redacted]	£28,786
R-mono	[redacted]	[redacted]			
Treatment waning effect at 7 years					
R^2	[redacted]	[redacted]	[redacted]	[redacted]	£13,763

R-mono	[redacted]	[redacted]			
Apply same subsequent treatment costs					
R^2	[redacted]	[redacted]	[redacted]	[redacted]	£19,580
R-mono	[redacted]	[redacted]			
Alternative utilities for PP states from Wild et al. (0.62)					
R^2	[redacted]	[redacted]	[redacted]	[redacted]	£16,073
R-mono	[redacted]	[redacted]			
Alternative utilities for PP states from Pereira et al. (0.45)					
R^2	[redacted]	[redacted]	[redacted]	[redacted]	£14,915
R-mono	[redacted]	[redacted]			

Table 6.15: Deterministic scenario analyses (conditional on ERG base-case) for R^2 versus R-mono: generalized gamma OS

Technologies	Total costs	Total QALYs	Incremental costs	Incremental QALYs	ICER (£/QALY)
ERG base-case					
R^2	[redacted]	[redacted]	[redacted]	[redacted]	£14,504
R-mono	[redacted]	[redacted]			
Use Generalised gamma for PFS both arms					
R^2	[redacted]	[redacted]	[redacted]	[redacted]	£14,227
R-mono	[redacted]	[redacted]			
Treatment waning effect at 3 years					
R^2	[redacted]	[redacted]	[redacted]	[redacted]	£24,156
R-mono	[redacted]	[redacted]			
Treatment waning effect at 7 years					
R^2	[redacted]	[redacted]	[redacted]	[redacted]	£11,539
R-mono	[redacted]	[redacted]			
Apply same subsequent treatment costs					
R^2	[redacted]	[redacted]	[redacted]	[redacted]	£16,184
R-mono	[redacted]	[redacted]			
Alternative utilities for PP states from Wild et al. (0.62)					
R^2	[redacted]	[redacted]	[redacted]	[redacted]	£14,214
R-mono	[redacted]	[redacted]			
Alternative utilities for PP states from Pereira et al. (0.45)					
R^2	[redacted]	[redacted]	[redacted]	[redacted]	£13,957
R-mono	[redacted]	[redacted]			

Table 6.16: Deterministic scenario analyses (conditional on ERG base-case) for R^2 versus R-mono: Gompertz OS

Technologies	Total costs	Total QALYs	Incremental costs	Incremental QALYs	ICER (£/QALY)
ERG base-case					

R^2	[redacted]	[redacted]	[redacted]	[redacted]	£25,535
R-mono	[redacted]	[redacted]			
Use Generalised gamma for PFS both arms					
R^2	[redacted]	[redacted]	[redacted]	[redacted]	£25,157
R-mono	[redacted]	[redacted]			
Treatment waning effect at 3 years					
R^2	[redacted]	[redacted]	[redacted]	[redacted]	£42,448
R-mono	[redacted]	[redacted]			
Treatment waning effect at 7 years					
R^2	[redacted]	[redacted]	[redacted]	[redacted]	£18,893
R-mono	[redacted]	[redacted]			
Apply same subsequent treatment costs					
R^2	[redacted]	[redacted]	[redacted]	[redacted]	£28,918
R-mono	[redacted]	[redacted]			
Alternative utilities for PP states from Wild et al. (0.62)					
R^2	[redacted]	[redacted]	[redacted]	[redacted]	£21,341
R-mono	[redacted]	[redacted]			
Alternative utilities for PP states from Pereira et al. (0.45)					
R^2	[redacted]	[redacted]	[redacted]	[redacted]	£18,333
R-mono	[redacted]	[redacted]			